![Roger Tell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Roger Tell
Hoofd Techniek/Wetenschap/O&O bij
ISOFOL MEDICAL AB
Profiel
Roger Tell is currently the Director at Vivesto AB since 2022 and the Chief Scientific & Medical Officer at Isofol Medical AB since 2019.
Previously, he worked as the Vice President-Clinical Development at Aprea Therapeutics AB. Dr. Tell obtained his doctorate degree from Karolinska Institutet in 1998.
Actieve functies van Roger Tell
| Bedrijven | Functie | Begin |
|---|---|---|
| ISOFOL MEDICAL AB | Hoofd Techniek/Wetenschap/O&O | 01-02-2019 |
| VIVESTO AB | Directeur/Bestuurslid | 25-05-2022 |
Eerdere bekende functies van Roger Tell
| Bedrijven | Functie | Einde |
|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Corporate Officer/Principal | 01-02-2019 |
Opleiding van Roger Tell
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
53
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivesto AB
 Vivesto AB Pharmaceuticals: GenericHealth Technology Develops cancer drugs based on nanotechnology for human and veterinary use | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Isofol Medical AB
 Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products | Health Technology |
